Protein biomarkers for assessing Inflammatory Bowel Disease (IBD) treatment efficiency

Completed

• Conditions: Inflammatory bowel disease (IBD), irritable bowel syndrome (IBS); Digestive System; Inflammatory bowel disease

• Registration Number: ISRCTN17818329
• Lead Sponsor: DiagNodus Ltd

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2015-01-12
• Last Update Posted: 3 July 2017

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

1. Patients with active IBD requiring conservative treatment;
2. Patients with IBD in remission
3. Patients with IBS
4. Healthy volunteers (a smaller group)

Exclusion Criteria

1. Concomitant colorectal disease other than IBD or IBS
2. Extensive colorectal surgery in the past

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1. Confirmation of sample collection method acceptance by patients<br>2. Confirmation of high quality of the collected material<br>3. Confirmation of the validity of biomarker quantification in the collected material for diagnostic and monitoring purposes

Secondary Outcome Measures

Name	Time	Method
1. Selection of optimal biomarkers for IBD diagnosis<br>2. Selection of optimal biomarkers for IBD therapy efficiency assessment